Patient characteristics
| Characteristic . | Base Sample* . | All CD . | Non-iMCD . | iMCD . | P† . | |
|---|---|---|---|---|---|---|
| UCD . | HHV-8-MCD . | |||||
| Total n | 30 757 413 | 442 | 156 | 32 | 254 | |
| Sex | ||||||
| Male | 14 041 488 (45.7) | 216 (48.9) | 82 (52.6) | 24 (75.0) | 110 (43.3) | |
| Female | 16 715 925 (54.3) | 226 (51.1) | 74 (47.4) | 8 (25.0) | 144 (56.7) | .007 |
| Mean age ± SD, y | 37.3 ± 21.8 | 49.1 ± 16.6 | 45.3 ± 16.4 | 50.9 ± 14.1 | 51.4 ± 16.6 | .001 |
| Age group, y | ||||||
| 0-17 | 7 597 776 (24.7) | 20 (4.5) | 9 (5.8) | 0 | 11 (4.3) | |
| 18-34 | 7 442 931 (24.2) | 83 (18.8) | 33 (21.2) | 7 (21.9) | 43 (16.9) | |
| 35-44 | 3 782 149 (12.3) | 56 (12.7) | 27 (17.3) | 3 (9.4) | 26 (10.2) | |
| 45-54 | 3 843 007 (12.5) | 101 (22.9) | 30 (19.2) | 9 (28.1) | 62 (24.4) | |
| 55-64 | 4 358 740 (14.2) | 134 (30.3) | 48 (30.8) | 9 (28.1) | 77 (30.3) | |
| ≥65 | 3 732 809 (12.1) | 48 (10.9) | 9 (5.8) | 4 (12.5) | 35 (13.8) | |
| Insurance | ||||||
| Medicare | 1 800 471 (5.9) | 31 (7.0) | 5 (3.2) | 2 (6.3) | 23 (9.1) | |
| Medicaid | 10 528 744 (34.2) | 108 (24.4) | 25 (16.3) | 16 (50.0) | 67 (26.4) | |
| Private | 18 428 198 (59.9) | 303 (68.6) | 126 (80.8) | 14 (43.8) | 164 (64.6) | |
| Mean continuous enrollment ± SD, y | 6.3 ± 3.8 | 6.3 ± 4.0 | 5.1 ± 3.8 | 4.8 ± 3.3 | 6.9 ± 4.0 | <.001 |
| Initial CD diagnosis setting | ||||||
| Inpatient | NA | 107 (22.2) | 17 (10.9) | 17 (53.1) | 73 (28.7) | |
| Outpatient | NA | 335 (77.8) | 139 (89.1) | 15 (46.9) | 181 (71.3) | |
| iMCD therapy | ||||||
| Chemotherapy‡ | NA | 23 (5.2) | 0 | 5 (15.6) | 18 (7.1) | |
| Immunomodulator§ | NA | 32 (7.2) | 3 (1.9) | 2 (6.3) | 27 (10.6) | .001 |
| Rituximab | NA | 39 (8.8) | 6 (3.8) | 8 (25.0) | 25 (9.8) | .380 |
| Siltuximab | NA | 25 (5.7) | 2 (1.3) | 1 (3.1) | 22 (8.7) | .001 |
| Corticosteroid | NA | 253 (57.2) | 75 (48.1) | 21 (65.6) | 157 (61.8) | |
| Tocilizumab | NA | 7 (1.6) | 2 (1.3) | 0 | 5 (1.9) | |
| Noneǁ¶ | NA | 170 (38.5) | 78 (50) | 8 (25.0) | 84 (33.1) | |
| N of patients with ≥1 therapeutic class | ||||||
| 1 | NA | 194 (43.9) | 68 (43.6) | 15 (46.9) | 111 (43.7) | |
| 2 | NA | 56 (12.7) | 10 (6.4) | 5 (15.6) | 41 (16.1) | |
| ≥3 | NA | 22 (5.0) | 0 | 4 (12.3) | 18 (7.1) | |
| Characteristic . | Base Sample* . | All CD . | Non-iMCD . | iMCD . | P† . | |
|---|---|---|---|---|---|---|
| UCD . | HHV-8-MCD . | |||||
| Total n | 30 757 413 | 442 | 156 | 32 | 254 | |
| Sex | ||||||
| Male | 14 041 488 (45.7) | 216 (48.9) | 82 (52.6) | 24 (75.0) | 110 (43.3) | |
| Female | 16 715 925 (54.3) | 226 (51.1) | 74 (47.4) | 8 (25.0) | 144 (56.7) | .007 |
| Mean age ± SD, y | 37.3 ± 21.8 | 49.1 ± 16.6 | 45.3 ± 16.4 | 50.9 ± 14.1 | 51.4 ± 16.6 | .001 |
| Age group, y | ||||||
| 0-17 | 7 597 776 (24.7) | 20 (4.5) | 9 (5.8) | 0 | 11 (4.3) | |
| 18-34 | 7 442 931 (24.2) | 83 (18.8) | 33 (21.2) | 7 (21.9) | 43 (16.9) | |
| 35-44 | 3 782 149 (12.3) | 56 (12.7) | 27 (17.3) | 3 (9.4) | 26 (10.2) | |
| 45-54 | 3 843 007 (12.5) | 101 (22.9) | 30 (19.2) | 9 (28.1) | 62 (24.4) | |
| 55-64 | 4 358 740 (14.2) | 134 (30.3) | 48 (30.8) | 9 (28.1) | 77 (30.3) | |
| ≥65 | 3 732 809 (12.1) | 48 (10.9) | 9 (5.8) | 4 (12.5) | 35 (13.8) | |
| Insurance | ||||||
| Medicare | 1 800 471 (5.9) | 31 (7.0) | 5 (3.2) | 2 (6.3) | 23 (9.1) | |
| Medicaid | 10 528 744 (34.2) | 108 (24.4) | 25 (16.3) | 16 (50.0) | 67 (26.4) | |
| Private | 18 428 198 (59.9) | 303 (68.6) | 126 (80.8) | 14 (43.8) | 164 (64.6) | |
| Mean continuous enrollment ± SD, y | 6.3 ± 3.8 | 6.3 ± 4.0 | 5.1 ± 3.8 | 4.8 ± 3.3 | 6.9 ± 4.0 | <.001 |
| Initial CD diagnosis setting | ||||||
| Inpatient | NA | 107 (22.2) | 17 (10.9) | 17 (53.1) | 73 (28.7) | |
| Outpatient | NA | 335 (77.8) | 139 (89.1) | 15 (46.9) | 181 (71.3) | |
| iMCD therapy | ||||||
| Chemotherapy‡ | NA | 23 (5.2) | 0 | 5 (15.6) | 18 (7.1) | |
| Immunomodulator§ | NA | 32 (7.2) | 3 (1.9) | 2 (6.3) | 27 (10.6) | .001 |
| Rituximab | NA | 39 (8.8) | 6 (3.8) | 8 (25.0) | 25 (9.8) | .380 |
| Siltuximab | NA | 25 (5.7) | 2 (1.3) | 1 (3.1) | 22 (8.7) | .001 |
| Corticosteroid | NA | 253 (57.2) | 75 (48.1) | 21 (65.6) | 157 (61.8) | |
| Tocilizumab | NA | 7 (1.6) | 2 (1.3) | 0 | 5 (1.9) | |
| Noneǁ¶ | NA | 170 (38.5) | 78 (50) | 8 (25.0) | 84 (33.1) | |
| N of patients with ≥1 therapeutic class | ||||||
| 1 | NA | 194 (43.9) | 68 (43.6) | 15 (46.9) | 111 (43.7) | |
| 2 | NA | 56 (12.7) | 10 (6.4) | 5 (15.6) | 41 (16.1) | |
| ≥3 | NA | 22 (5.0) | 0 | 4 (12.3) | 18 (7.1) | |
Data are presented as n (%) of patients unless otherwise indicated.
NA, not applicable; SD, standard deviation.
Base sample refers to all patients in the database with or without CD.
Comparison of all non-iMCD cases (UCD and HHV-8-MCD) with iMCD cases.
Bendamustine, bleomycin, cisplatin, cyclophosphamide, dacarbazine, decitabine, doxorubicin etoposide, vinblastine, and vincristine.
Anakinra, bortezomib, cyclosporin, eculizumab, hydroxychloroquine, lenalidomide, mycophenolate mofetil, sirolimus, and thalidomide.
None refers to no treatment claims for iMCD-directed treatments.